20 Participants NeededMy employer runs this trial

Botensilimab + Balstilimab for Colorectal Cancer

Recruiting at 1 trial location
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: National Cancer Institute (NCI)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This phase II trial tests the effect of the botensilimab in combination with balstilimab in treating patients with stage II/III colorectal adenocarcinoma with detectable circulating tumor (ct) deoxyribonucleic acid (DNA) in the blood. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab may be an effective combination to remove any remaining microscopic cancer cells in the bloodstream in patients with stage II/III colorectal adenocarcinoma. In addition, clearing the ctDNA from the blood may serve as an early indicator of treatment response.

Who Is on the Research Team?

KP

Kanwal P Raghav

Principal Investigator

University of Texas MD Anderson Cancer Center LAO

Are You a Good Fit for This Trial?

This trial is for adults (18+) with stage II or III colorectal adenocarcinoma who have cancer DNA detected in their blood after standard treatment. Participants need to be in reasonably good health, with adequate blood counts and organ function.

Inclusion Criteria

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN
I am 18 years old or older.
Absolute neutrophil count ≥ 1,000/mcL
See 15 more

Exclusion Criteria

I have not used immune-suppressing drugs in the past week or trial drugs in the past month.
History of allergic reactions to compounds chemically or biologically similar to botensilimab and balstilimab
Receiving any other investigational agents
See 18 more

What Are the Treatments Tested in This Trial?

Interventions

  • Balstilimab
  • Botensilimab

Trial Overview

The study is testing a combination of two immunotherapy drugs, botensilimab and balstilimab, given after standard treatment to see if they can help the immune system clear remaining cancer cells from the bloodstream. The trial includes regular scans and blood tests.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Treatment (balstilimab, botensilimab)Experimental Treatment5 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+